Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review evaluates the clinical experience of using low-dose oral minoxidil for treating alopecia and highlights the ongoing concerns about its potential side effects without reporting new clinical results.

This study observed that DDAIP-HCl enhanced the permeation of minoxidil through human cadaver skin, suggesting potential for improved treatment efficacy in male pattern hair loss.

This article provides regulatory updates, legal briefs, and industry news, reporting no new clinical findings.

This review explores the mechanisms and clinical trials of topical minoxidil for hair loss but presents no new clinical findings, emphasizing the need for better understanding of hair loss etiology for effective treatments.

Combining microneedling with minoxidil leads to better hair regrowth than using minoxidil alone.

This study found that the patient receiving microneedling and platelet-rich plasma treatment showed earlier significant improvements and high satisfaction compared to the patient treated with microneedling and topical minoxidil.

This article discusses the use of low-dose oral minoxidil as an off-label treatment for androgenetic alopecia but reports no new clinical results.

This study identified a new minoxidil analogue called triaminodil in an illegal hair-growth supplement, but no data on its chemical, toxicological, or pharmacological properties are available yet.

This study found that combining needle-free intradermal minoxidil delivery with standard topical minoxidil therapy improved early hair growth parameters and satisfaction in women with early-stage female pattern hair loss compared to topical therapy alone, with no serious adverse events reported over the 10-week period.

This study found that for managing early-onset androgenetic alopecia in men, minoxidil monotherapy is cost-effective at a $50,000 willingness-to-pay threshold, while combining minoxidil with platelet-rich plasma becomes cost-effective at a $100,000 threshold.

This study reviewed cases of ocular adverse events linked to minoxidil use, finding central serous chorioretinopathy as the most common issue, with symptoms improving after discontinuation in many cases, yet causality remains uncertain.

In this randomized controlled trial, combining 4-weekly microneedling with 5% minoxidil significantly increased hair density and diameter in men with androgenetic alopecia compared to minoxidil alone, while side effects were minor and tolerable.

This review discusses the effects of minoxidil on human skin fibroblasts, reporting its potential to inhibit lysyl hydroxylase activity and DNA synthesis, suggesting it may have antifibrotic applications for collagen-related skin conditions.

In this case study, a 17-year-old male using topical minoxidil 5% for beard growth developed peripheral edema, which resolved after discontinuing the drug, highlighting a rare but significant systemic side effect of minoxidil's use.

This study found that the combination of platelet-rich plasma with topical minoxidil and finasteride was more effective in treating androgenetic alopecia than the conventional minoxidil and finasteride therapy alone.

This study found that dracorhodin perchlorate improved wound healing in diabetic rats by regulating the TLR4 pathway and related inflammatory factors.

In this study, researchers found that dissolving microneedles made with hyaluronic acid enhanced the effectiveness of minoxidil in reducing hair loss and promoting hair growth in alopecia-affected mice more effectively than topical minoxidil alone, while using only 10% of the drug amount.

This study suggests that a microemulsion formulation of Minoxidil effectively enhances drug delivery through hair follicles, showing significant follicular response alterations in an alopecia model.

The researchers reported that combining platelet-rich plasma with minoxidil showed the most improvement in androgenetic alopecia compared to other treatment groups, but also had more pain as a side effect.

This study retrospectively observed that combining microneedle minoxidil with triamcinolone acetonide showed clinical efficacy in treating alopecia areata, a condition marked by sudden patchy hair loss.

This randomized clinical trial found that both topical ethinylestradiol 0.01% combined with minoxidil 2% and minoxidil 2% alone were similarly effective in enhancing hair growth for female pattern hair loss, though minoxidil alone was better tolerated with fewer side effects over 24 weeks.

This study reported that while topical minoxidil exhibits hair regrowth in androgenetic alopecia, oral minoxidil 5 mg/day was more effective than topical forms after six months, with low doses also potentially effective for women and other hair loss types.

This review discusses the multifunctional role of PKM2 in promoting cardiac repair and regeneration, highlighting its potential as a therapeutic target in cardiovascular medicine, but reports no new experimental results.

This study reviewed the effectiveness and safety of Minoxidil for treating alopecia and found that concentrations of 2% to 5% effectively promoted hair growth, especially when combined with other therapies like microneedling, despite manageable local side effects.

Mitoxantrone is effective for treating acute leukemia, especially in older patients, with a lower risk of heart damage.

Low-dose oral minoxidil doesn't affect blood pressure in patients taking blood pressure meds.

In this study, there was no significant difference in hair growth between patients with extensive alopecia areata treated with 1% minoxidil and those receiving a placebo.

In this case study, a 23-year-old man initially suspected of having minoxidil-induced pericarditis was ultimately diagnosed with cardiac angiosarcoma, highlighting the need to consider malignancy in cases of recurrent pericarditis in young adults.